Elevance Health Q3 2026 调整后 EPS $6.99 大超预期并上调全年指引，但约 $1.85 靠非经营收益、会员流失，盘中跌约 2.2% 呈 sell-the-news

Introduction & Market Context
Elevance Health (NYSE:ELV) presented its third-quarter 2026 earnings results on October 21, 2026, reporting adjusted diluted earnings per share of $6.99 that significantly exceeded analyst expectations of $4.70. Despite the 48.7% earnings beat and raised full-year guidance, shares declined 2.24% to $430.32, reflecting investor scrutiny over the composition of the earnings surprise, which included substantial non-operating gains.
The company’s presentation materials revealed that approximately $0.50 of the beat came from operating outperformance across Medicaid, Medicare Advantage, and Individual ACA businesses, while roughly $1.85 per share stemmed from favorable non-operating items, primarily investment income valuation adjustments. This mix appears to have tempered market enthusiasm despite the company’s improved outlook and confidence in delivering at least 12% adjusted diluted EPS growth in 2027.
Quarterly Performance Highlights
Elevance Health’s third-quarter results demonstrated solid operating execution alongside favorable benefit expense trends. Operating revenue reached $50.4 billion, up 0.7% from the prior year’s $50.1 billion, driven by higher premium yields, CarelonRx product revenue, and service fees. However, this growth was partially offset by lower health plan membership, which declined 1.1% to 44.9 million members from 45.4 million a year earlier.
The following table presents the company’s overall financial performance for the quarter:
The benefit expense ratio improved 70 basis points year-over-year to 90.6%, reflecting better medical cost management across multiple business lines. This improvement was particularly notable in Medicaid, Medicare Advantage, and Individual ACA segments. However, the adjusted operating expense ratio increased 90 basis points to 11.3%, reflecting targeted investments in capabilities designed to drive future growth.
Operating cash flow totaled $1.3 billion for the quarter, up from $1.1 billion in the prior year, benefiting from favorable working capital dynamics. The company maintained its adjusted operating margin at 2.7%, flat compared to the prior year despite revenue growth.
As outlined in the presentation’s key highlights summary, management emphasized that results exceeded expectations due to favorable benefit expense performance and strong operating execution across the enterprise:
Segment Performance Analysis
The Health Benefits segment generated operating revenue of $43.4 billion, up 2.6% year-over-year, though operating margin compressed to 1.0% from 1.4% in the prior year. This 40 basis point decline reflected strategic investments in future growth initiatives, partially offset by the improved benefit expense ratio. Membership declined across Medicare Advantage, Medicaid, and Employer Group risk-based businesses, though this was partially offset by growth in Commercial fee-based membership.
In contrast, the Carelon health services segment delivered strong performance with operating revenue of $19.3 billion, up 5.4% year-over-year, and operating margin expansion of 50 basis points to 4.7%. CarelonRx benefited from higher pharmacy spending and specialty pharmacy strength, while operating expenses declined. Carelon Services showed continued expansion of risk-based solutions with improved performance across these programs.
Despite Carelon’s revenue growth, the segment reported declines in key volume metrics, with adjusted scripts falling 2.8% to 82.6 million and consumers served declining 6.8% to 91.0 million, reflecting the impact of lower health plan membership on the pharmacy and services businesses.
Strategic Initiatives
Elevance Health’s presentation emphasized a comprehensive approach to building sustainable competitive advantages through four key capability areas: medical cost management, member engagement, Carelon expansion, and provider connectivity. The company reported identifying more than $300 million in anticipated savings year-to-date through enhanced medical cost management capabilities.
The following graphic illustrates the company’s integrated strategy for scaling capabilities across these four areas:
A particularly notable achievement highlighted in the presentation was the more than 400 basis point increase year-to-date in the percentage of health plan benefit expense managed by Carelon. This deepening integration between the health plan and services businesses represents a core element of the company’s differentiation strategy. Additionally, the company reported a 15% reduction in avoidable admissions for oncology program members and a greater than 60% reduction in documentation requests for health systems using its HealthOS platform.
The company’s strategic focus centers on what management describes as a "flywheel" model that integrates three key elements: optimizing the core business, investing in growth, and accelerating performance. This model connects the Health Benefits segment, serving approximately 45 million medical members, with Carelon’s integrated portfolio of whole health solutions serving approximately 91 million consumers.
Forward-Looking Statements
Elevance Health raised its 2026 adjusted diluted EPS guidance to at least $29.00, up from the previous baseline of at least $26.00. More significantly, the company increased its 2026 earnings baseline—which excludes certain non-recurring items—to at least $26.75. From this higher baseline, management expressed confidence in delivering at least 12% adjusted diluted EPS growth in 2027, supported by Health Benefits margin improvement, broader adoption of Carelon’s value-based solutions, greater operating efficiency, and disciplined capital deployment.
The company also raised its 2026 operating cash flow guidance to at least $6.5 billion, reflecting improved working capital management and stronger operating performance.
Elevance’s long-term growth algorithm targets at least 12% average annual growth in adjusted diluted EPS, driven by high single-digit to low double-digit compound annual growth in adjusted operating gain and approximately 4% contribution from capital deployment. The company outlined specific revenue growth targets by segment: mid to high single-digit CAGR for Health Benefits, high teens to low twenties CAGR for Carelon Services, and low double-digit CAGR for CarelonRx.
The presentation detailed specific financial targets for each major business segment, with Health Benefits expected to achieve mid-single-digit operating margins and Carelon targeting mid-single-digit margins over the long term. For the consolidated enterprise, management aims to expand the adjusted operating margin to a range of 5.0% to 6.0% from the current 3.8% level reported for 2025.
The company’s capital allocation strategy dedicates 50% of capital to M&A and organic reinvestment, 30% to share repurchases, and 20% to dividends. This allocation reflects management’s focus on programmatic M&A targeting integrated solutions that strengthen health plan competitiveness while maintaining consistent returns to shareholders. Notably, Elevance has raised its dividend for 15 consecutive years and currently offers a 1.56% yield.
Market Reaction and Analyst Perspectives
Despite the substantial earnings beat and raised guidance, Elevance Health shares declined in trading following the results, falling from $440.18 to $430.32. The stock remains near the upper end of its 52-week range of $274.84 to $450.69, approximately 4.5% below the recent high.
The muted market reaction appears to reflect investor focus on the composition of the earnings beat, particularly the $1.85 per share contribution from non-operating items that may not recur. Analysts questioned management during the earnings call about the sustainability of the company’s 2027 growth targets and the degree to which they depend on Medicaid margin recovery. Management emphasized that growth expectations are not reliant on any single business line and expect contributions from improved health benefits margins, Carelon expansion, and operating efficiency gains.
Questions also centered on Medicaid rate adequacy and whether recent rate increases are sufficient to offset elevated cost trends. Executives indicated that recent rate updates helped improve second-half margins but acknowledged that additional progress is needed in 2027 as states continue adjusting rates to align with underlying medical costs.
The Medicare Advantage outlook drew particular attention, with management reiterating expectations for margin improvement in 2027 toward the company’s long-term target range of 3% to 5%. Individual ACA results have exceeded expectations, supported by stronger retention and a shift toward lower-premium bronze plans, with year-end membership expected to reach at least 1.2 million.
Chief Executive Gail Boudreaux emphasized the breadth of the quarter’s performance: "Elevance Health delivered strong third quarter results with Medicaid, Medicare Advantage, and individual ACA each contributing to our better-than-expected performance." She added that the company remains "confident in our ability to deliver at least 12% adjusted diluted earnings per share growth in 2027" from the raised earnings baseline.
Chief Financial Officer Mark Kaye highlighted that "improved operating performance across the enterprise supports both our increased 2026 earnings guidance and a higher earnings baseline as we enter 2027," suggesting management views the quarter’s results as indicative of sustainable operational improvements rather than one-time benefits.
While InvestingPro data indicates the stock may be trading below its fair value estimate and rates the company’s financial health as "GREAT" with a score of 3.16 out of 5, investors appear to be taking a wait-and-see approach regarding the sustainability of margin improvements and the company’s ability to navigate ongoing challenges in Medicaid cost trends, commercial affordability pressures, and regulatory uncertainty.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.